(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 December 2008 (11.12.2008)

PCT

(10) International Publication Number
WO 2008/150565 A3

(51) International Patent Classification:
A61K 31/495 (2006.01) *G01N 33/68* (2006.01)
A61P 9/10 (2006.01)

(21) International Application Number:
PCT/US2008/058063

(22) International Filing Date: 24 March 2008 (24.03.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/941,210 31 May 2007 (31.05.2007) US

(71) Applicant *(for all designated States except US)*: **CV THERAPEUTICS, INC.** [US/US]; 3172 Porter Drive, Palo Alto, CA 94304 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **BLACKBURN, Brent** [US/US]; 633 Almond Avenue, Los Altos, CA 94022 (US). **JERLING, Marcus** [SE/SE]; Stavgardsgatan 30, S-167 56 Bromma (SE). **WOLFF, Andrew** [US/US]; 2140 Taylor Street #803, San Francisco, CA 94133 (US).

(74) Agents: **HARTRUM, J., Elin** et al.; Cv Therapeutics, Inc., 3172 Porter Drive, Palo Alto, CA 94304 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(88) Date of publication of the international search report:
2 April 2009

(54) Title: RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE

(57) Abstract: This invention is directed to the use of ranolazine to reduce the risk of adverse coronary events in a mammalian patient. Typically, the natriuretic peptide is associated with coronary disease, acute coronary syndrome, and/or diastolic dysfunction. Ranolazine may be administered to the patient as an intravenous solution or in an oral dose.

WO 2008/150565 A3